Dartmouth-Hitchcock Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Dartmouth-Hitchcock Medical Center sits in the top decile of US sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count).

427 total trials 52 currently recruiting 300 completed early-phase tilt top decile by trial count

Dartmouth-Hitchcock Medical Center: 427 sponsored US clinical trials, 52 recruiting.

Dartmouth-Hitchcock Medical Center sponsors 427 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 300 completed. 25 of these trials are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.

Top-decile sponsor footprint

Dartmouth-Hitchcock Medical Center ranks in the top decile of sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

300 of 352 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

427 total, page 6 of 9

COMPLETED NA

Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis

NCT02404974

COMPLETED NA

Using The HOPES Program in Transition Care

NCT02420340

COMPLETED

Electrical Activity of Diaphragm as a Means to Predict Extubation Success in Preterm Infants

NCT02144363

COMPLETED NA

Vascular Physician Offer and Report (VAPOR) Trial

NCT02220686

COMPLETED Phase 1

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404

COMPLETED

Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

NCT02188758

TERMINATED Phase 2

Study of Promethazine for Treatment of Diabetic Gastroparesis

NCT02130622

TERMINATED Phase 2

ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

NCT01984268

COMPLETED NA

A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer

NCT02159157

COMPLETED

Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

NCT02071056

COMPLETED Phase 2

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

NCT02160808

COMPLETED NA

Randomized Controlled Trial (RCT) of a Motivational Decision Support System

NCT02086162

TERMINATED

Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung

NCT02113397

COMPLETED NA

Evaluating a Shared Decision Making Program for Crohn's Disease

NCT02084290

COMPLETED NA

Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI

NCT02084303

COMPLETED Phase 1

Phase I Trial of DAR-901

NCT02063555

COMPLETED NA

Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.

NCT02010021

COMPLETED NA

Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes

NCT01722643

COMPLETED Phase 2

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

NCT02139280

TERMINATED

Patient Derived Breast Cancer Xenografts

NCT01750164

TERMINATED

Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer

NCT01836640

COMPLETED

Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea

NCT02056327

COMPLETED NA

Behavioral Treatment of Adolescent Substance Use

NCT02063984

TERMINATED

Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas

NCT01849952

COMPLETED NA

Hand Hygiene and Hospital Acquired Infections

NCT02252562

TERMINATED Phase 2

Hyperbaric Oxygen for Ulcerative Colitis

NCT02144350

COMPLETED NA

A Proof-of-principle Study of HBO-SRS for Brain Metastases

NCT01850563

COMPLETED NA

Differentiating the Effects of Substance P and Beta-endorphin

NCT01854177

COMPLETED Phase 4

Clozapine for Cannabis Use in Schizophrenia

NCT01639872

COMPLETED Phase 1

BR in Patients With CLL With Comorbidities and/or Renal Dysfunction

NCT01832922

COMPLETED NA

Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders

NCT01834794

COMPLETED NA

Reducing Disability in Older Adult Cancer Survivors

NCT01709344

COMPLETED NA

Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness

NCT01779440

TERMINATED Phase 3

Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

NCT01774604

TERMINATED NA

Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway

NCT01653366

COMPLETED

OPERA Database - Crohn's Protocol

NCT01720368

COMPLETED

IBD-OPERA Database, UC Protocol

NCT01708395

COMPLETED

Tumor Specific Plasma DNA

NCT01617915

TERMINATED Early Phase 1

A Study of the Effect of Vinca Alkaloids on c-Jun N-terminal Kinase (JNK) Phosphorylation in Patients With Chronic Lymphocytic Leukemia (CLL)

NCT01463852

COMPLETED NA

Fluoroscopy-guided Versus Traditional Placement of Epidural Catheters

NCT02678039

COMPLETED NA

A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection

NCT01645852

COMPLETED NA

New Hampshire Medicaid Wellness Incentive Program

NCT02515981

COMPLETED NA

The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing

NCT01580423

COMPLETED Phase 2

Risperidone and Desipramine in Alcohol Use and Schizophrenia

NCT01411085

TERMINATED

Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?

NCT02026726

COMPLETED

Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment

NCT01460914

COMPLETED

Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia

NCT01460238

COMPLETED NA

Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach

NCT01792765

COMPLETED NA

Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial

NCT01583400

COMPLETED NA

Reduction in IV Associated Contamination

NCT01426217

← Previous Page 6 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 44
Phase 2 40
Phase 3 6
Phase 4 19

What is open in the Dartmouth-Hitchcock Medical Center pipeline

52 recruiting of 427 indexed (12% open); 300 completed (70%).

Phase mix: 25 late (III/IV) vs 84 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Dartmouth-Hitchcock Medical Center: open-pipeline peers nationwide

Peers matched on 427 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 0%10%20%30% Total trials Recruiting share Dartmouth-Hitchcock Medical CenterUniversity of Illinois at ChicagoVanderbilt UniversityChildren's Hospital of PhiladelphiaNovo Nordisk A/SFriends Research InstituteAntonios LikourezosOregon State UniversityUniversity of Massachusetts, Amherst
Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 427 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this Dartmouth-Hitchcock Medical Center page

427 registered trials is a research-attention snapshot, not an endorsement of Dartmouth-Hitchcock Medical Center or any single study.

  • 52 of Dartmouth-Hitchcock Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Dartmouth-Hitchcock Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dartmouth-Hitchcock Medical Center pipeline card: 427 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.